Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
Antitumor effects of combined transfer of P16 and cytokine genes were investigated in this study. The adenovirus harboring the P16 gene (AdP16) and murine granulocyte-macrophage colony-stimulating factor gene (AdGM-CSF) were utilized for the treatment of established tumors. The mice were inoculated subcutaneously with Renca cells and, 6 days later, received an intratumoral injection of AdP16 in the presence or absence of AdGM-CSF. The results demonstrated that tumor-bearing mice treated with AdP16 in combination with AdGM-CSF showed more potent inhibition of tumor growth and survived much longer than did mice treated with AdP16, AdGM-CSF, adenovirus expressing beta-galactosidase, or phosphate-buffered saline alone (P<.01). The tumor mass showed obvious necrosis and inflammatory cell infiltration, and more CD(4)(+) and CD(8)(+) T cells infiltrating the tumor after combined therapy. After combined therapy, the expression of MHC-1 (H-2K(d)) and Fas molecules on freshly isolated tumor cells increased greatly. The activity of specific cytotoxic T lymphocytes was also found to be induced more significantly after the combined therapy (P<.01). Our results demonstrated that combined therapy with P16 and GM-CSF genes can inhibit the growth of established tumors in mice significantly and induce antitumor immunity of the host efficiently.
Wang
Linhui
L
The Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai, China. wlhui@online.sh.cn
Qi
Xiaosheng
X
Sun
Yinghao
Y
Liang
Li
L
Ju
Dianwen
D
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000628:therapy; D003131:Combined Modality Therapy; D004274:DNA, Recombinant; D005260:Female; D005434:Flow Cytometry; D018014:Gene Transfer Techniques; D019942:Genes, p16; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics*; D006183:H-2 Antigens / Q000276:immunology; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy; D007694:Killer Cells, Natural / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014162:Transfection; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000378:metabolism
D004274:DNA, Recombinant; D006183:H-2 Antigens; C024755:H-2K(K) antigen; D019014:fas Receptor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor